Correlation Between Microsoft and Provectus Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both Microsoft and Provectus Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Provectus Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Microsoft and Provectus Biopharmaceuticals, you can compare the effects of market volatilities on Microsoft and Provectus Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Provectus Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Provectus Biopharmaceutica.

Diversification Opportunities for Microsoft and Provectus Biopharmaceutica

-0.15

Correlation Coefficient

Microsoft  Provectus Biopharmaceutica

Good diversification

The 3 months correlation between Microsoft and Provectus is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Provectus Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Provectus Biopharmaceutica and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Provectus Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Provectus Biopharmaceutica has no effect on the direction of Microsoft i.e., Microsoft and Provectus Biopharmaceutica go up and down completely randomly.

Pair Corralation between Microsoft and Provectus Biopharmaceutica

If you would invest  41,700  in Microsoft on September 23, 2024 and sell it today you would earn a total of  1,960  from holding Microsoft or generate 4.7% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	4.76%
Values	Daily Returns

Microsoft  vs.  Provectus Biopharmaceuticals

Microsoft

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Provectus Biopharmaceutica

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Provectus Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Provectus Biopharmaceutica is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Microsoft and Provectus Biopharmaceutica

The main advantage of trading using opposite Microsoft and Provectus Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Provectus Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Provectus Biopharmaceutica will offset losses from the drop in Provectus Biopharmaceutica's long position.

The idea behind Microsoft and Provectus Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..